Five Dividend Aristocrats—Johnson & Johnson, Procter & Gamble, McDonald's, Coca-Cola, and Automatic Data Processing—continue to demonstrate reliable dividend growth streaks of 25 years or more. Each company shows strong earnings and cash flow, supporting ongoing dividend increases despite some risks like litigation, market pressures, or execution challenges. These stocks offer diversified, defensive income options across healthcare, consumer staples, restaurants, beverages, and payroll technology sectors, making them suitable for long-term income-focused investors. Their multi-decade growth track records and solid financials suggest they can sustain payouts through economic cycles.
Johnson & Johnson has delivered a strong 28% total return year-to-date in 2026, outperforming major benchmarks like the S&P 500 ETF and healthcare sector ETF XLV. Despite solid second-quarter results and an upgraded full-year 2026 guidance driven by ...
Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johns...
Johnson & Johnson and AbbVie both posted strong quarterly results but differ in dividend approach and business focus. J&J, a Dividend King with 64 years of raises, offers a modest 2.02% yield supported by diversified pharma and MedTech products. AbbV...
The iShares Core High Dividend ETF (HDV) relies heavily on energy and pharmaceutical sectors, with Exxon Mobil, Chevron, Johnson & Johnson, and AbbVie making up about 26% of its assets. Exxon and Johnson & Johnson are rated very safe due to strong ca...
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
